New treatment for kidney diseases
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called sibeprenlimab to see if it can safely control three types of kidney disease. It may help people whose disease is hard to manage with current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of the three kidney diseases: primary membranous nephropathy, immune-mediated focal segmental glomerulosclerosis, or minimal change disease.
- If you have primary membranous nephropathy, you need to have high levels of PLA2R antibodies and not have responded to previous treatment.
- If you have focal segmental glomerulosclerosis or minimal change disease, your disease must be under control but you need ongoing immunosuppressive medicine to keep it that way.
- You cannot have had a kidney transplant, other serious autoimmune diseases, active infections, or uncontrolled blood pressure.
- You must not have type 1 diabetes or poorly controlled type 2 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This study tests a new medicine called surovatamig for adults with a specific type of kidney disease caused by the body's own antibodies (anti-PLA2R antibody-positive membranous nephropathy). The medicine may help reduce kidney damage and improve kidney function.
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
This study tests a new medicine called JMT601 for people with primary membranous nephropathy (a kidney condition causing protein leakage). The goal is to see if the medicine can reduce protein in the urine while being safe.
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.